Good morning, and welcome to the Wave Life Sciences Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded and webcast.

Wave Life Sciences has won Food and Drug Administration rare-pediatric-disease designation for its WVE-N531 drug candidate in the neuromuscular genetic disease Duchenne muscular dystrophy. The ...

Fintel reports that on August 9, 2024, Jones Trading initiated coverage of Wave Life Sciences (NasdaqGM:WVE) with a Buy recommendation. As of August 6, 2024, the average one-year price target for ...

Designation highlights significant unmet needs in DMD; dystrophin data from potentially registrational FORWARD-53 trial of WVE-N531 are on track for 3Q 2024 In previous Part A trial, WVE-N531 ...

Wave Life Sciences (WVE) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.20 per share a year ago. These ...

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...